Deflecting?

New Post Public Reply Private Reply Replies (0) Message Board
FanMail homerbedloe #28590
303
I said nothing about intentionally breaking any SEC rules. I commented on your statement that a quiet period runs from when a company registers with the SEC until 40 days after the stock starts trading. Perhaps that was inaccurate on your part; perhaps I was missing something (which I suggested could be the case); perhaps I was misinterpreting or misunderstanding what is or is not allowed in a "quiet period." I also said that if I was not mistaken in my understanding, then I wondered why no communications that are repeatedly suggested here were being made. I made no accusation (and still am not, at least at this point).

Asking me to make suggestions about how to solve the issues that are plaguing Generex/NuGen is no different from asking the patient for suggestions on how to cure a condition when the patient tells the doctor that what s/he is doing is not helping. I did not agree to hold the positions of CEO/President/CoB, and would not have even were I asked, because I am not qualified. I am not qualified as an structural engineer, either, but I can point out when cracks appear in the foundation, even though I cannot tell you why they occurred or how to correct them. If I am one of the owners of the building, however, you can bet that I will point out what may be engineering/architectural/construction problems if I see them. In this particular case, Moscato is the engineer, architect, and builder.

I read lots of things about what people here say about the company, and I read what Moscato says, too. What people say and what people do are sometimes completely different things, so I focus on what is done, and not what is said. You can tell me repeatedly that you are going to send me $50 in the mail, but until the money actually arrives, what you tell me is, quite literally, valueless, because I have nothing to show for your words. Same principle applies here.

As for my investor status, I originally invested in the early 00's, back when I had a Scottrade account, before TDA bought it. Bought a bunch of shares over time, and "let it ride," based on what I had read about the goals/plans of the company, what apparently was 'in the pipeline," and what funding was being obtained. Reverse split (more than one? - I do not recall, but I think so) eventually came, and I still let it sit. At some point after Moscato "officially" took over, I bought many, many more shares, because I, too, believed the "vision." Initially, it appeared it might be coming true, so I bought more, even when that meant that I would be "averaging up," because I still believed good things were in the cards. Over the last couple of years, however, what the company has promoted, versus what this company has accomplished, have been two very different things, and it has been similar to a small child running from one toy to another, without ever actually engaging with one. (Kind of like "Randy" on Christmas morning in A Christmas Story.) I have sold a significant portion of my share of GNBT. When NUGX "slipped under Moscato's ever-watchful eye" and started trading, I also sold some of those early dividend shares. I continue to hold positions in "both companies."

Final thought - I recall AMZN, too. What I do not recall is that 20 years after they went public that the SP was substantially down, with no unequivocal indication that the SP would rise. Seems that Bezos' vision including building one brick on top of another, and not a brick here, a log there, a stone somewhere else. Funny you use Amazon; both it and Generex have been publicly traded relatively the same period of time.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 4

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 7

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 4

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 7

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 7

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 0

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 5

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 3

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 3

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Auto Loan Preapproval for Smart Buying

Updated Category News Views 8

A Fresh Perspective on Auto Loan Preapproval Diving into the maze of auto financing, sometimes you gotta stop and smell the coffee—that's where this HelloNation piece comes in, serving a dose of clarity for potential car buyers. Brad Bailey, the top dog at Red River Credit Union, steps into the fray to break it down. Gaining Financial Insight Ahead of the Game Think of...

Continue Reading
ArcelorMittal's Vision for Decarbonization in Europe Highlights

Updated Category News Views 147

ArcelorMittal's Commitment to Decarbonization ArcelorMittal is on a transformative journey to reshape its decarbonization strategy in Europe. The company has laid out a roadmap that prioritizes the replacement of traditional blast furnaces with lower carbon emissions facilities, specifically hydrogen-ready DRI-EAF systems. This endeavor marks a pivotal step forward in...

Continue Reading
Will International Stocks Outperform U.S. Markets This Year?

Updated Category News Views 193

Can International Stocks Surpass U.S. Performance? According to recent insights from a Vanguard economist, the landscape for stock investments is shifting, suggesting that international markets might finally outpace U.S. stocks. After facing challenges early in the year, U.S. stocks have rebounded impressively. The S&P 500 index has increased by approximately 16%...

Continue Reading
MellingMedical Secures Federal Supply Schedule for Pharmaceuticals

Updated Category News Views 216

MellingMedical Receives Federal Supply Schedule Contract MellingMedical proudly announces its successful acquisition of a federal contract specifically designed for essential pharmaceuticals. This new agreement plays a pivotal role in ensuring America's veterans have timely access to critical medications and health products. Understanding the Federal Supply Schedule The...

Continue Reading
GBM Gains Edge with Dr. Paik's Strategic Appointment

Updated Category News Views 9

A Heavyweight Joins the Global Battery Materials Camp This isn't your run-of-the-mill executive shuffle, folks. Global Battery Materials Corp. (GBM) has just brought in a marksman in the battery world—Dr. Yi Hyon Paik. The guy doesn't just dabble; he's chalked up over 30 years in the trenches of battery technology, electronic materials, and the big leagues of energy...

Continue Reading